HomeMarket NewsCurrency NewsWeakness in the rupee to benefit pharma, says IIFL

Weakness in the rupee to benefit pharma, says IIFL

Sanjiv Bhasin of IIFL shared his reading and outlook on market and specific stocks.

Profile image

By Anuj Singhal   | Latha Venkatesh  August 17, 2018, 12:42:49 PM IST (Published)

Sanjiv Bhasin of IIFL says weakness in the domestic currency is likely to benefit pharma and not tech.



“We have a target of Rs 750 on Sun Pharma and we remain extremely bullish. We think the weakness in the rupee should ideally be played out not by IT but by pharma,” he said.

>Follow our full coverage on Indian rupee here

Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!